
Abalone Bio
Abalone Bio is a YC Winter 2020 (W20) company. Based in Emeryville, CA, USA. Team of 14.
About Abalone Bio
Summary
Abalone Bio discovers and develops activating antibodies for disease targets that conventional drug discovery has failed to drug. Its platform engineers cells to screen hundreds of millions of antibodies per experiment for functional activity rather than structure or binding, generating large proprietary datasets that train machine learning models to find and optimize rare hits against difficult targets such as GPCRs. The lead programs target obesity and metabolic disease, aiming to replicate the weight-loss efficacy of GLP-1 drugs without the gastrointestinal side effects that drive patient dropout.
Go-to-market
Abalone Bio sells both proprietary drug programs and platform-access partnerships to pharmaceutical companies, with deals structured around upfront payments and downstream milestones.
From the Y Combinator listing
We create activating antibodies to treat diseases others can’t.
Abalone Bio is tackling challenging undrugged targets underlying diseases affecting millions, focusing first cell-specific antibody drugs to treat obesity and metabolic disease without the GI side effects that cause 25% of GLP-1 drug patients to quit after 1 year. + High throughput experimental measurement uniquely leverages AI/ML: We’ve engineered cells to measure antibodies for pharmacological activity, not just structure or binding like others, 100 million at a time, 100X+ the throughput of others. With our large, proprietary activity datasets, we uniquely leverage ML to both unlock the discovery of rare hits and generate optimized hits for challenging targets, starting with G-protein coupled receptors (GPCRs) + Proven success: We have developed antibody agonists (activators) for 2 out of the 8 G-protein coupled receptors ever drugged by biotech. + Pharma traction: We’ve secured 3 partnerships with $3M in revenue and $125M in downstream value. + Externally validated science: We’ve been awarded $7M in non-dilutive grant funding for platform and program development.
Facts
- Healthcare / Healthcare -> Drug Discovery and Delivery
- Emeryville, CA, USA
- 14
- Active
- Early
Founders (2)
- Gustavo Pesce
- Richard Yu
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works